linjc16/ctgov huggingface dataset:
Evaluation of the Prevalence of BPPV and Longterm Effects of Its Therapy Using the Rotundum Device in Retirement Homes

Study Overview
=================
Brief Summary
-----------------
Benign paroxysmal positional vertigo (BPPV) is one of the most common types of vertigo, especially in elderly. Therefore the investigators have set the goal to evaluate the prevalence of BPPV and its therapy using the Rotundum device in elderly living in retirement homes. Furthermore the investigators use a questionnaire to evaluate possible predictive signs to improve the diagnosis of this disease.

Official Title
-----------------
Evaluation of the Prevalence of BPPV and Longterm Effects of Its Therapy in Retirement Homes

Conditions
-----------------
Benign Paroxysmal Positional Vertigo

Intervention / Treatment
-----------------
* Diagnostic Test: Epley maneuver/Barbeque maneuver


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lives in retirement home/has vertigo/has signed the informed consent Exclusion Criteria: severe heart failure untreated cardiac arrythmia severe autonomic Dysregulation untreated epilepsy untreated cervical vertebral body fracture inability to follow the test weight over 150kg or under 40kg height below 140cm or over 200cm bedridden already participated this study participant is connected to the study team
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Evaluation of prevalence of BPPV<br>Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device. | Diagnostic Test: Epley maneuver/Barbeque maneuver<br>* Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of BPPV | subjects | Subjects (outcome measure) are assessed during the first 4 Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of predictive Factors | Questionnaire answers | Is assessed after all subjects have been tested (after 5 Years) |
Renal Fractional Flow Reserve in Renal Artery Stenting

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine potential utility of renal fractional flow reserve in prognosis predicting after renal stent implantation.

Official Title
-----------------
Prognostic Value of Renal Fractional Flow Reserve in Hypertensive Patients With Renal Artery Stenosis Qualified to Renal Artery Stenting

Conditions
-----------------
Renal Artery Stenosis, Hypertension

Intervention / Treatment
-----------------
* Procedure: Renal artery stenting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least moderate (60% or more) renal artery stenosis with atheromatic appearance in angiography Hypertension defined according to WHO criteria Age 18-75 years Signed informed consent obtained Exclusion Criteria: Bilateral renal artery stenosis or significant renal artery stenosis in solitary kidney Contraindications to percutaneous renal angioplasty with stenting Atrophy of the kidney supplied with stenosed artery Other well known secondary reason for hypertension Chronic heart failure NYHA II-IV Significant valvular heart disease qualified for surgery Persistent atrial fibrillation Renal failure with GFR below 30ml/min

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hypertensive patients<br>Hypertensive patients with at least moderate renal artery stenosis | Procedure: Renal artery stenting<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure improvement |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kidney function preservation |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fractional flow reserve, Revascularization, Prognosis, Hemodynamics, Hypertension
Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan

Study Overview
=================
Brief Summary
-----------------
The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Detailed Description
-----------------
Background: Surgical site infections are hospital-acquired, vary from one hospital to another, and can cause significant postoperative morbidity, mortality, and prolonged hospital stay. Aim: The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan. Methods: Postsurgical wound samples were collected and processed in a microbiology laboratory using standard microbiological techniques. Antibiotic susceptibility tests were performed using 13 antibiotics covering the gram-positive and gram-negative bacteria using the disc diffusion test.

Official Title
-----------------
Antibiotic Profile of Pathogenic Bacteria Isolated From Postsurgical Site Infections in Public Hospitals in Northern Jordan

Conditions
-----------------
Bacterial Infections, Antibiotic Resistant Infection, Surgical Site Infection

Intervention / Treatment
-----------------
* Drug: ciprofloxacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post-Surgical Wound Infection Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Wound infection<br>Patients with surgical site infection as diagnosed by the attending physician | Drug: ciprofloxacin<br>* Antibiotics used in vitro n the study<br>* Other names: oxacillin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive culture | Positive swab culture from the wound | August 2019 to October 2019 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gram stain and type of Bacteria | Gram stain and type of Bacteria grown in culture media | August 2019 to October 2019 | 
| Antibiotic Susceptibility | Antibiotic Susceptibility to the isolated organisms | August 2019 to October 2019 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antimicrobial, hospital, post-surgical infection, surgery
Reduced Manipulation of the Aorta and Neurobehavioral Outcome Trial

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine whether aortic manipulation in patients undergoing coronary bypass graft surgery leads to increased incidence of microemboli and subsequent impairment of neurobehavioral function.

Detailed Description
-----------------
Patients who have coronary artery bypass graft (CABG) surgery must have their aorta (the large blood vessel that is attached to the heart) clamped with an instrument. There are two basic ways of manipulating the aorta during surgery. One way is to place a single clamp across the aorta. The other way is to place more than one clamp on the aorta in several places. Both methods are used, but it is not known if one way is better than the other. The purpose of this study is to compare the two methods of clamping to see if one way is better than the other, and to determine whether patients who undergo reduced manipulation of the aorta have fewer microemboli delivered to the brain during CABG surgery and have a lower incidence of neurobehavioral problems following surgery. Microemboli are tiny fat particles that enter the bloodstream during surgery, circulate to the brain, and block tiny blood vessels, causing brain deficits. Participants in this trial will be randomly classified into one of two groups: the experimental group will undergo cross clamping of the aorta with a single clamp and be given retrograde cardioplegia for heart protection, and the control group will undergo cross clamping of the aorta with multiple clamps and be given antegrade cardioplegia for heart protection. Neurobehavioral assessments will be accomplished with a comprehensive battery of neurological and neuropsychological tests.

Conditions
-----------------
Coronary Disease

Intervention / Treatment
-----------------
* Procedure: single aorta clamp with retrograde cardioplegia
* Procedure: multiple aorta clamps with antegrade cardioplegia


Participation Criteria
=================
Eligibility Criteria
-----------------
Participants must be English-speaking patients, 50 years of age or older, and undergoing elective CABG surgery. Participants of both genders and all races are eligible.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: single aorta clamp with retrograde cardioplegia|nan|
|Procedure: multiple aorta clamps with antegrade cardioplegia|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery bypass graft surgery, CABG surgery, neurobehavioral impairment, aorta clamping, aorta manipulation, microemboli
Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System

Study Overview
=================
Brief Summary
-----------------
The Crux Vena Cava Filter (VCF) Registry is a clinical study, sponsored by Volcano Corporation, to evaluate the short and long term performance and clinical outcomes of the Crux Vena Cava Filter System.

Detailed Description
-----------------
The Crux VCF Registry is a non-randomized clinical study, sponsored by Volcano Corporation, to evaluate the short and long term performance and clinical outcomes of the Crux VCF System. The registry includes consecutive patients treated with the Crux VCF in a post-market (commercial) setting with data collection at the implant procedure through 2 years post implant or to filter retrieval, whichever comes first. Patients may also be enrolled (roll-in) from a previous Crux VCF implant within the previous 6 months. Follow up assessment will be performed at 6, 12 and 24 months post-implant and at the time of retrieval, if performed.

Official Title
-----------------
Volcano Crux Vena Cava Filter Registry

Conditions
-----------------
Pulmonary Embolism, Venous Thromboembolism, Deep Vein Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient is >18 years of age. Patient or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent. Scheduled for and receives a Crux VCF implant or; Have previously had a Crux VCF implanted within the previous 6 months. Exclusion Criteria: Patient is scheduled for filter implant, but did not have a Crux VCF filter implanted due to anatomical exclusions or technical failures. Patients unwilling or unable to comply with the protocol and provide informed consent. Female patient of childbearing potential who is pregnant (she must have negative pregnancy test within the 48 hours prior to implantation and any retrieval procedure) Patient is participating in another device or drug clinical trial that interferes with this protocol follow up schedule.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention of Pulmonary Embolism | The primary objective is to evaluate the long term clinical outcomes of patients treated with the Crux VCF for the prevention of PE over a two year period or up to filter retrieval, whichever comes first. | 2 years |
Does Asthma Phenotype Have Impact on Disease Control

Study Overview
=================
Brief Summary
-----------------
The application of biomarkers that are more closely associated with eosinophillic airway inflammation, such as measurements of FeNO level, cell count in induced sputum or bronchial reactivity could improve asthma control by better directing treatment. A systematic review and meta-analysis is to be conducted to assess the efficacy of tailoring asthma intervention on clinical symptoms compared with exhaled nitric oxide or induced sputum count.

Detailed Description
-----------------
AHR used as outcome

Official Title
-----------------
Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyper Responsiveness Ensure Stable Disease Faster

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Pulmicort


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: positiv mannitol asthma diagnose Exclusion Criteria: other lung disease

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pulmicort<br>ICS and LABA - based on ACQ and FeNO | Drug: Pulmicort<br>* ACQ and FeNO<br>* Other names: RCT study;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Control of asthma based on an algorithm | Based on ACQ and FeNO | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The use of NO and sputum cell count as a marker in asthma management | Based on ACQ and FeNO | 2 years |
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination

Official Title
-----------------
A Randomised Phase II Study to Investigate the Feasibility and Benefits of Combining ZD1839 and Cisplatin/5FU, as Induction Therapy, in Patients With Locally and Advanced Squamous Cell Carcinoma of the Head and Neck

Conditions
-----------------
Squamous Cell Cancer, Cancer of Head and Neck

Intervention / Treatment
-----------------
* Drug: gefitinib
* Drug: cisplatin
* Drug: 5-flourouracil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of written informed consent Patients with histologically proven primary SCCHN Aged 18 or over Exclusion Criteria: Patients eligible for surgery with curative intent Other co-existing malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ Exclude UCNT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: gefitinib|nan|
|Drug: cisplatin|nan|
|Drug: 5-flourouracil|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the objective tumour response rate between cisplatin/5FU and cisplatin/5FU and ZD1839 combination in these patients |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare safety and tolerability in these patients |  |  |
Comparative Outcomes Between Foot Cast and Short Leg Cast in the Patients With Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)

Study Overview
=================
Brief Summary
-----------------
This study aims to compare outcomes of short leg cast and foot cast for treatment acute fifth metatarsal fracture (Zone II).

Detailed Description
-----------------
A randomized controlled trial will conducts between January 2017 and January 2019, participants with acute fifth metatarsal fracture (Zone II) will recruit for this study at the orthopedic outpatient clinic of a police general hospital, Bangkok, Thailand. A total of 100 patients will randomly allocate to receive foot cast or short leg cast. acute closed fracture of proximal fifth metatarsal (zone II) patients.

Official Title
-----------------
Comparative Outcomes Between Foot Cast and Short Leg Cast in the Patients With Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)

Conditions
-----------------
Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)

Intervention / Treatment
-----------------
* Device: short foot cast
* Device: short leg cast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:acute closed fracture of proximal fifth metatarsal (zone II) with following criteria History of trauma and pain at lateral side of foot Tenderness at base of 5th metatarsal Radiographic finding shown fracture line at proximal 5th metatarsal bone Exclusion Criteria: more than 1 week comminuted or multiple fracture Open fracture Ligament and tendon injury Previous injury complication: nonunion, delayed union Malignancy refuse to inform consent

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: foot cast<br> | Device: short foot cast<br>* metatarsal foot cast<br>|
| Active Comparator: short leg cast<br> | Device: short leg cast<br>* full short leg cast<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS | visual analog score | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AOFAS | foot score | 8 weeks | 
| union rate | radiographic union | 8 weeks | 
| complication | skin ulcer or compartment syndrome | 8 weeks |
CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab

Study Overview
=================
Brief Summary
-----------------
The Geriatric 8 (G8), Vulnerable Elders Survey (VES-13), and Cancer and Aging Research Group (CARG) questionnaires are among the main tests whose purpose is to predict the risk of chemotherapy-induced toxicity (CRT) and allow treatment. Investigators aimed to investigate the effect of using the G8, VES13, and CARG scales in the geriatric age group in cancer patients receiving nivolumab treatment in predicting side effects.

Detailed Description
-----------------
Investigator aimed to examine whether the G8, VES13, and CARG scales can shed light on clinicians in predicting side effects during the use of nivolumab in geriatric cancer patients. In the chemotherapy unit, demographic information, diagnosis date of the disease, previous treatments, comorbidities, and CARG, VES13, and G8 questionnaires will be recorded face-to-face to the patients who meet the study criteria. In addition, routine hemogram and biochemistry tests, which were requested by the patient's follow-up physician before Nivolumab treatment and which will be requested by the patient's own physician during follow-up visits, will be recorded prospectively. Side effects that may occur during nivolumab treatment will be pursued at each visit. CTCA v.6. will be used for grading. inclusion criteria 1-Advanced cancer patients whose nivolumab treatment was started by the physician followed up (independent of diagnosis) 2-60 years and over, 3-ECOG performance score 0-1 4-Patients who signed the informed consent form exclusion criteria Under 60 years old Ecog score >1

Official Title
-----------------
CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab

Conditions
-----------------
Nivolumab Related Toxicity

Intervention / Treatment
-----------------
* Drug: there is no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced stage cancer patients who have been treated with nivolumab be over 60 years old Exclusion Criteria: be under the age of 60

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group 1<br>Advanced cancer patients over 65 years of age receiving nivolumab | Drug: there is no intervention<br>* there is no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| grade 3-4 nivolumab toxicity | grading will be made according to the CTCA V.6 | one year from first patient enrolled |